Jan 10 (Reuters) - Sorrento Therapeutics Inc said on Friday it had received a proposal from a private equity fund interested in acquiring a majority or all of its outstanding shares, valuing the company at as much as $993 million.
The drugmaker said it was reviewing the non-binding proposal of up to $7 per Sorrento share. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Our Standards: The Thomson Reuters Trust Principles.